BTK and mantle cell lymphoma: Although ibrutinib has shown encouraging results in the treatment of MCL, the emergence of acquired resistance in MCL cells remains an ongoing clinical challenge, with alterations in the BCR-BTK pathway potentially contributing significantly to resistance.